OREANDA-NEWS. July 29, 2015. Takeda Pharmaceutical Company Limited (“Takeda”) today announced that it has been included for the eleventh consecutive year in the FTSE4Good Global Index of the FTSE4Good Index Series, one of the world’s premier indices for Socially Responsible Investment (SRI)*.

Provided by FTSE Russell**, the FTSE4Good Global Index is a benchmark SRI index and is one of the most important indices for investors who take into consideration corporate social responsibility (CSR) initiatives of each company when making investment decision. FTSE Russell applies its own criteria*** for selection from some 2,000 companies in 25 markets in developed countries. As of June 30, 2015, 803 companies were included from around the world. Takeda has once again been selected for this Index for having met FTSE’s criteria in the areas of environmental, social and governance.

In addition to the FTSE4Good Global Index, Takeda is included in other benchmark SRI indices such as the Dow Jones Sustainability Asia Pacific Index compiled by Dow Jones & Company of the United States, and the Morningstar Socially Responsible Investment Index (MS-SRI) compiled by Morningstar Japan K.K.

As a pharmaceutical company committed to improving people’s lives, Takeda will continue fulfilling its social responsibility as a global entity, with a view towards realizing its mission, “We strive towards better health for people worldwide through leading innovation in medicine.”
 

* SRI evaluates investments in companies not only in terms of financial performance, but also with an emphasis on corporate social responsibility performance from social, ethical, environmental, and other perspectives.

** An independent company owned by the London Stock Exchange, FTSE Russell provides global index and analytical solutions.

*** FTSE Russell uses environmental, social and governance criteria that consist of 14 themes. The themes applied to each company are determined based on the nature of business conducted.